Inmune Bio, Inc. (INMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.44+7.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INMB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | — | 0.1 | 0.0 | 0.2 | 0.4 | 0.2 | 0.0 | — | 0.0 |
| Total Revenues | — | 0.1 | 0.0 | 0.2 | 0.4 | 0.2 | 0.0 | — | 0.0 |
| Operating Expenses & Income | |||||||||
| R&D Expenses | — | 20.7 | 33.2 | 20.3 | 17.1 | 20.5 | 5.9 | 3.3 | 3.4 |
| Other Operating Expenses, Total | — | — | — | — | (1.3) | (1.2) | 0.1 | — | — |
| Operating Income | (20.2) | (47.4) | (42.6) | (29.7) | (26.0) | (29.2) | (12.2) | (7.8) | (12.4) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | — | 0.8 | 2.3 | 2.0 | — | — | — | — |
| Other Non-Operating Income / Expenses | 1.8 | 1.5 | 0.6 | (0.3) | — | (1.2) | 0.1 | — | — |
| EBT, Incl. Unusual Items | — | 45.9 | 42.1 | 30.0 | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — | 0.0 |
| Net Income | |||||||||
| Net Income | (18.5) | (45.9) | (42.1) | (30.0) | (27.3) | (30.3) | (12.1) | (7.7) | (12.4) |
| Per Share | |||||||||
| Basic EPS | (0.69) | (1.86) | (2.11) | (1.67) | (1.52) | (1.88) | — | — | — |
| Diluted EPS | (0.69) | (1.86) | (2.11) | (1.67) | (1.52) | (1.88) | — | — | — |
| Basic Weighted Avg Shares | 26.7 | 24.8 | 19.9 | 18.0 | 17.9 | 16.1 | — | — | — |
| Diluted Weighted Avg Shares | 26.7 | 24.8 | 19.9 | 18.0 | 17.9 | 16.1 | — | — | — |
| Supplemental | |||||||||
| EBIT | (20.2) | (47.4) | (42.6) | (29.7) | (26.0) | (29.2) | (12.2) | (7.8) | (12.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.